Let your imagination sail away with this awesome @Photoshop tutorial by Jenny Le. https://t.co/UvLbgjf4hn https://t.co/y9Bjm1I31d
It's #NationalBossDay. Unfortunately, we can't all be blessed with a fantastic boss. There are plenty of people who… https://t.co/pQOt3G88kv
No Monday morning traffic jams out here 🙌 📷 by den-belitsky https://t.co/d0k17zfdi1
Lycotec has developed and a new liver-targeting delivery technology for orally administered drugs, vitamins, and other bioactive molecules.
This technology could benefit those drugs which particular targeting liver specific biochemical pathways, for example statins.
Results of the proof of concept pharmaco-dynamic clinical trial, for our proprietary formulation LycoStatinTM, containing 20 mg of Simvastatin are presented on the figure below.
Lycotec technology promotes selective delivery of drug molecules to the liver, and consequently reduces their presence, and hence side-effects, in extra-hepatic tissues.
The technology can be applied for other small molecules as well as for peptides and some proteins.
Lycotec technologies in the media both in the UK and Internationally